1. MRONJ risk is a pre-extraction question
MRONJ risk should be identified before dental extraction. The risk is not just a complication to mention at the end of consent. It can change whether you restore, endodontically treat, monitor, extract, or refer.
The practical question is simple: has this patient received a drug that affects bone turnover or angiogenesis, and does the dental procedure involve bone trauma? If the answer is yes, slow down and risk-stratify the case.
This topic links closely with simple vs surgical extraction planning, dental extraction in patients taking anticoagulants or antiplatelets, and osteoradionecrosis risk before extraction in irradiated jaws.
Senior rule
Before extracting, ask why the patient is taking the medication. Cancer-dose antiresorptive therapy is a very different risk conversation from osteoporosis-dose therapy.
2. The medication name is not enough
A medication history that only says “bisphosphonate” is incomplete. You need the drug name, route, dose pattern, indication, duration, last dose if relevant, and whether the patient is also receiving chemotherapy, steroids, immunotherapy, or antiangiogenic medication.
Oral alendronate for osteoporosis is not the same risk profile as intravenous zoledronic acid for metastatic bone disease. Denosumab for osteoporosis is not the same as higher-dose denosumab used in oncology. Same family, different clinical risk.
| Medication group | Common examples | Why it matters before extraction |
|---|---|---|
| Oral bisphosphonates | Alendronate, risedronate, ibandronate | Usually osteoporosis-dose; risk is lower but not zero |
| Intravenous bisphosphonates | Zoledronic acid, pamidronate | Higher concern, especially cancer-dose regimens |
| Denosumab | Osteoporosis-dose or oncology-dose schedules | Risk depends strongly on indication and dosing pattern |
| Antiangiogenic drugs | Bevacizumab, sunitinib and related agents | May impair healing and increase MRONJ concern |
| Combination therapy | Antiresorptive plus cancer therapy or steroids | Risk is higher and referral is often safer |
3. Cancer-dose therapy is the major red flag
The highest-risk extraction decisions usually involve patients receiving antiresorptive or antiangiogenic therapy for cancer-related bone disease, multiple myeloma, metastatic breast cancer, metastatic prostate cancer, or other oncology indications.
These patients often receive stronger or more frequent regimens, may be medically complex, and may also have chemotherapy, immunosuppression, anemia, steroids, or poor healing capacity. A routine extraction plan may be unsafe without specialist input.
Dental infection still needs source control
In high-risk patients, do not ignore infection. Decide carefully between endodontics, extraction, drainage, and referral.
4. Osteoporosis-dose therapy usually needs careful dentistry, not panic
Patients taking antiresorptive medication for osteoporosis usually have a lower MRONJ risk than oncology patients. That does not mean the risk is ignored. It means you should avoid unnecessary extraction, control active dental disease early, use atraumatic technique, and give clear consent.
Do not tell patients to stop osteoporosis medication on your own. Stopping or delaying therapy can carry medical risk, especially with denosumab. Any interruption decision belongs with the prescribing clinician and, when needed, oral surgery or medical specialists.
Clean wording
“This medication may slightly affect jaw healing after extraction. Your risk appears different from cancer-dose therapy, but we still need careful planning, consent, and follow-up.”
5. Red flags before extraction
MRONJ risk increases when medication exposure combines with local infection, poor oral hygiene, periodontal disease, traumatic extraction, denture trauma, smoking, diabetes, steroids, chemotherapy, or previous MRONJ.
The biggest clinical red flag is existing exposed bone, a non-healing socket, a fistula probing to bone, unexplained jaw pain, swelling, suppuration, loosening teeth without periodontal explanation, or altered sensation.
| Finding before extraction | Why it matters | Better action |
|---|---|---|
| Previous MRONJ | High recurrence or progression concern | Refer before invasive treatment |
| Cancer-dose antiresorptive therapy | Higher MRONJ risk | Specialist planning is usually safer |
| Exposed bone or fistula to bone | Possible existing MRONJ | Do not perform routine extraction; refer |
| Acute dental infection | Infection itself increases risk and harm | Control infection and plan source management |
| Traumatic denture ulcer over bone | Chronic mucosal trauma can expose bone | Adjust denture and assess healing |
| Steroids, diabetes, smoking, chemotherapy | Healing risk is higher | Lower threshold for referral and review |
6. First ask whether extraction is avoidable
The safest extraction is the one the patient does not need. If the tooth can be restored predictably, treated endodontically, smoothed, or monitored safely, that may reduce bone trauma. But this should not become neglect. A hopeless infected tooth can also be dangerous.
The decision is not “never extract.” The decision is whether extraction is truly indicated, whether alternatives are reasonable, and whether the extraction should be done in primary care or by an oral surgery team.
Senior rule
Avoid unnecessary extraction, but do not leave uncontrolled dental infection just because the patient is MRONJ-risk.
7. Dental infection changes the balance
Active infection is one of the most important local risk factors. A draining abscess, severe periodontitis, unrestorable caries, or recurrent infection may make source control necessary even in a patient at MRONJ risk.
In high-risk patients, source control should be planned carefully. Sometimes that means endodontic treatment instead of extraction. Sometimes extraction is still required, but with specialist input, antibiotic planning when appropriate, atraumatic technique, and close follow-up.
Abscess present?
Antibiotics alone do not remove the source. Decide drainage, endodontics, extraction, or referral from the infection pattern.
8. Drug holidays are not a simple dental instruction
It is tempting to think the answer is “stop the medication before extraction.” That is too simple and can be unsafe. Bisphosphonates remain in bone for a long time, so short interruptions may not meaningfully remove risk. Denosumab timing is different and stopping or delaying it can create medical risk.
Do not independently stop bisphosphonates, denosumab, or cancer therapy. If medication timing might matter, coordinate with the prescribing clinician and oral surgery team. The dental plan should not create a fracture, cancer, or systemic treatment problem.
Safe phrase
“I would not advise stopping the medication myself. I would coordinate with the prescriber or oral surgery team because the benefit and risk of interruption depend on the drug and indication.”
9. Consent should be specific
Consent should explain that healing may be delayed and there is a risk of exposed bone, pain, infection, non-healing socket, need for further treatment, and specialist referral. The level of emphasis depends on the patient’s risk category.
Do not frighten a low-risk osteoporosis patient as if they are an oncology patient. But also do not under-consent a cancer-dose denosumab or zoledronic acid patient as if the extraction is routine.
| Risk category | Consent focus | Planning focus |
|---|---|---|
| Osteoporosis-dose, no extra risk factors | Low but real delayed-healing/MRONJ risk | Atraumatic technique and review |
| Long duration plus local infection | Higher healing concern | Control infection and plan carefully |
| Cancer-dose antiresorptive therapy | Meaningful MRONJ risk | Referral or specialist planning |
| Previous MRONJ or exposed bone | Possible recurrence or active disease | Do not treat as routine extraction |
10. Technique should reduce trauma
When extraction is appropriate, the surgical plan should reduce trauma as much as possible. This means careful soft tissue handling, controlled luxation, avoiding unnecessary bone removal, smoothing sharp bone, irrigation, and closure when indicated.
The procedure may need oral surgery referral if the tooth is badly broken down, impacted, infected, or surgically difficult. The higher the MRONJ risk, the less acceptable it is to “try and see.”
Difficult extraction expected?
If flap, bone removal, or sectioning is likely, decide early whether the case should be referred.
11. Follow-up matters because MRONJ is delayed
MRONJ is not diagnosed the day after extraction. The concern is delayed healing, exposed bone, infection, pain, or a socket that does not close normally over time. This is why review and safety-net instructions matter.
Tell the patient to return if they notice exposed bone, persistent pain, swelling, pus, bad taste, loosening teeth, numbness, or a socket that is not healing. A high-risk patient should not disappear after extraction.
Patient-friendly explanation
“Because of your medication history, we need to watch healing more carefully. If you see exposed bone, ongoing pain, swelling, discharge, or the socket does not close, contact us early.”
12. MRONJ vs osteoradionecrosis
MRONJ and osteoradionecrosis can both involve non-healing exposed jaw bone, but the risk history is different. MRONJ is linked to antiresorptive or antiangiogenic medications. Osteoradionecrosis is linked to previous radiation therapy to the jaws.
Do not mix the two histories. A patient with head and neck radiation needs a separate extraction risk pathway. A patient with both radiation and antiresorptive therapy is even more complex and should be referred.
Previous jaw radiation?
Use the osteoradionecrosis pathway before extraction in irradiated jaws. It is not the same as MRONJ risk.
13. Common mistakes
| Mistake | Why it is risky | Better habit |
|---|---|---|
| Asking about medication after extraction | Risk was missed at the decision stage | Screen before invasive treatment |
| Treating all bisphosphonate patients the same | Risk depends on indication, dose, route, and duration | Separate osteoporosis-dose from cancer-dose therapy |
| Stopping medication without coordination | Can create medical harm | Discuss with prescriber or oral surgery team |
| Ignoring active infection | Infection itself can worsen risk | Plan source control carefully |
| No consent about delayed healing | Patient is surprised by a known risk | Explain MRONJ risk in proportion to risk category |
| No follow-up plan | Non-healing socket may be detected late | Review healing and safety-net clearly |
14. OSCE answer
A strong OSCE answer does not simply say “bisphosphonate equals no extraction.” It shows risk stratification, alternatives, consent, medical coordination, and referral judgment.
Model answer
“Before extraction, I would ask specifically about antiresorptive and antiangiogenic medications, including bisphosphonates, denosumab, cancer drugs, route, dose, indication, duration, and previous MRONJ. I would assess local risk factors such as dental infection, periodontal disease, denture trauma, smoking, diabetes, steroids, chemotherapy, and poor oral hygiene. If the patient is on osteoporosis-dose therapy with low additional risk, extraction may be possible with careful consent, atraumatic technique, and review. If the patient is on cancer-dose therapy, has previous MRONJ, exposed bone, a non-healing socket, or complex medical risk, I would refer before invasive treatment. I would not stop bisphosphonates or denosumab myself, and would coordinate with the prescriber or oral surgery team if medication timing is being considered.”
15. FAQ
Does oral alendronate mean extraction is forbidden?
No. Many osteoporosis-dose patients can still receive dental care, including extraction when necessary. The case needs risk assessment, consent, atraumatic technique, and follow-up.
Is cancer-dose denosumab higher risk than osteoporosis-dose therapy?
Yes. Oncology-dose antiresorptive therapy is generally a higher-risk MRONJ situation and often needs specialist planning before extraction.
Should the dentist stop bisphosphonates before extraction?
No, not independently. Bisphosphonates remain in bone for a long time, and medication decisions should be coordinated with the prescriber or specialist team.
Should denosumab be delayed before extraction?
Not as a routine dental instruction. Denosumab timing can have medical consequences, so any adjustment should be coordinated with the prescribing clinician and oral surgery team.
What signs suggest existing MRONJ?
Exposed bone, a fistula probing to bone, a non-healing socket, persistent jaw pain, swelling, suppuration, loosening teeth without periodontal cause, or altered sensation should raise concern.
When should I refer before extraction?
Refer before extraction if the patient has cancer-dose therapy, previous MRONJ, exposed bone, suspected MRONJ, complex medical risk, antiangiogenic therapy, or a difficult extraction requiring surgical bone trauma.
How DentAIstudy helps
DentAIstudy turns MRONJ risk into a pre-extraction decision pathway instead of a vague “bisphosphonate warning.”
- Flashcards for high-risk MRONJ medications and red flags
- OSCE scripts for consent, referral, and medication history
- Tables separating osteoporosis-dose and cancer-dose therapy
- Decision prompts for extraction, endodontics, monitoring, and referral
Related oral surgery articles
References
- American Association of Oral and Maxillofacial Surgeons — Medication-Related Osteonecrosis of the Jaw: 2022 Update | Position paper on MRONJ definition, risk factors, staging, prevention, dental management, and treatment strategies.
- American Dental Association — Osteoporosis Medications and Medication-Related Osteonecrosis of the Jaw | ADA oral health topic page on antiresorptive medications, osteoporosis-dose risk, risk factors, and dental management.
- Scottish Dental Clinical Effectiveness Programme — Oral Health Management of Patients at Risk of MRONJ | Guidance for dental teams managing patients prescribed antiresorptive or antiangiogenic drugs.
- Scottish Dental Clinical Effectiveness Programme — MRONJ Guidance Supplement, January 2024 Update | Update supplement covering newer evidence and medication-risk considerations for MRONJ guidance.
- StatPearls / NCBI Bookshelf — Bisphosphonate-Related Jaw Osteonecrosis | Clinical overview of bisphosphonate-related osteonecrosis, diagnosis, risk factors, and management principles.
- Singh N, et al. Dental Management of Medication-Related Osteonecrosis of the Jaw. 2023. | Review discussing dental prevention, treatment planning, and management considerations for MRONJ-risk patients.